392
Participants
Start Date
October 29, 2024
Primary Completion Date
November 30, 2028
Study Completion Date
November 30, 2028
BBO-10203
Participants will receive assigned dose of BBO-10203 orally once daily
Trastuzumab
Participants will receive trastuzumab as infusion or subcutaneous injection every 21 days
Fulvestrant
Patients will receive Fulvestrant as an intramuscular injection every 28 days (additional dose on C1D15)
Ribociclib
Patients will receive Ribociclib orally once a day (21 days on treatment, 7 days off)
FOLFOX
Patients will receive FOLFOX as infusion every 14 days
Bevacizumab
Patients will receive bevacizumab as infusion every 28 days
RECRUITING
Scientia Clinical Research, Randwick
RECRUITING
Peter MacCallum Cancer Centre, Melbourne
RECRUITING
Columbia University Irving Medical Center, New York
RECRUITING
Memorial Sloan Kettering Cancer Center, New York
RECRUITING
Moffitt Cancer Center, Tampa
RECRUITING
SCRI Oncology Partners, Nashville
RECRUITING
Indiana University Simon Comprehensive Cancer Center, Indianapolis
RECRUITING
SCRI at Mary Crowley, Dallas
RECRUITING
University of Texas Southwestern Medical Center, Dallas
RECRUITING
The University of Texas MD Anderson Cancer Center, Houston
RECRUITING
University of Texas San Antonio (UTSA), San Antonio
RECRUITING
University of California Los Angeles, Los Angeles
RECRUITING
Fred Hutchinson Cancer Center, Seattle
RECRUITING
Massachusetts General Hospital, Boston
RECRUITING
Dana-Farber Cancer Insitute, Boston
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
INDUSTRY